LA JOLLA, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the?NASDAQ Global Market?(NASDAQ:MNOV) and the JASDAQ Market of the?Tokyo Stock Exchange?(Code Number: 4875), today announced that it has received a Notice of Allowance from the?Chinese Patent Office?for a pending patent application which covers MN-001 (tipelukast) for the treatment of idiopathic pulmonary fibrosis (IPF).
News
MediciNova to Attend the Morgan Stanley Global Healthcare Conference in New York
LA JOLLA, Calif., Aug. 29, 2019 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the?NASDAQ Global Market?(NASDAQ:MNOV) and the JASDAQ Market of the?Tokyo Stock Exchange?(Code Number: 4875), today announced that?MediciNova?… […]
News
MediciNova Appoints Kazuko Matsuda to its Board of Directors
LA JOLLA, Calif., July 24, 2019 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the appointment… […]
News
MediciNova to Present at the Ladenburg Thalmann 2019 Healthcare Conference in New York
LA JOLLA, Calif., Sept. 11, 2019 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the?NASDAQ Global Market?(NASDAQ:MNOV) and the JASDAQ Market of the?Tokyo Stock Exchange?(Code Number: 4875), today announced that?Yuichi Iwa… […]
